![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, December 10, 2020 8:29:39 PM
Let's reverse engineer HGEN's reverse engineered statement of 37% improvement for lenzilumab. How did HGEN come up with 37%? They divided the initial recovery target for patients of 257 by the new target of 402. That is faulty methodology. The trial was not going to hit stat sig at 257 so an increase greater than actual efficacy was needed to try and hit stat sig.
We know 29% improvement was needed to hit the minimum statistical value to not shut down the trial due to futility. That was most likely set at higher than p= .05 with an eye towards it achieving p= .05 with the increased number of patients at full enrollment. If lenzilumab had hit that p= threshold than no additional patients would be needed. That 37% additional patients were needed to achieve stat sig shows efficacy must be below 29%.
If you believed HGEN's explanation in their PR then you've been had.
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM